RANDOMISED, MULTICENTRE, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MONTELUKAST VS. PLACEBO IN PATIENTS WITH EROSIVE/INFLAMMATORY OSTEOARTHRITIS OF THE HANDS. MOTHER Study.

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521802-17-00

Enrollment

160

Registered

2025-10-23

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erosive/inflammatory osteoarthritis of the hands

Brief summary

Difference in pain intensity (PID) at rest of the most affected hand with respect to baseline pain at 24 weeks of treatment with Montelukast xx mg, compared to placebo, measured through the VAS.

Interventions

DRUGMontelukast C

DRUGPlacebo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Difference in pain intensity (PID) at rest of the most affected hand with respect to baseline pain at 24 weeks of treatment with Montelukast xx mg, compared to placebo, measured through the VAS.	—

Countries

Italy, Portugal, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026